Zai Lab (ZLAB) Liabilities and Shareholders Equity (2016 - 2026)
Zai Lab (ZLAB) posted Liabilities and Shareholders Equity of $1.1 billion for Q1 2026, down 6.54% sequentially from $1.2 billion in Q4 2025, and down 6.61% YoY from $1.2 billion in Q1 2025.
Analysis
Zai Lab (ZLAB) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
Zai Lab has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $1.1 billion in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 6.61% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 5.99% YoY) and the FY2025 annual result came in at $1.2 billion, down 1.13% from the prior year.
- Liabilities and Shareholders Equity eased to $1.1 billion in Q1 2026 per ZLAB's latest filing, from $1.2 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $1.5 billion in Q1 2022 and troughed at $985.3 million in Q3 2024.
- A 5-year average of $1.2 billion and a median of $1.2 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
- The widest YoY moves for Liabilities and Shareholders Equity: up 32.67% in 2022, down 25.14% in 2022.
- Over 5 years, Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then retreated by 15.07% to $1.0 billion in 2023, then increased by 14.42% to $1.2 billion in 2024, then declined by 1.13% to $1.2 billion in 2025, then slipped by 6.54% to $1.1 billion in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.1 billion, $1.2 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Zai Lab | 2.94 Bn | 2.23 Bn | 58.15 Mn | 1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Bn |
| Mar 31, 2026 | 1.10 Bn |
| Dec 31, 2025 | 1.17 Bn |
| Sep 30, 2025 | 1.16 Bn |
| Jun 30, 2025 | 1.16 Bn |
| Mar 31, 2025 | 1.17 Bn |
| Dec 31, 2024 | 1.19 Bn |
| Sep 30, 2024 | 985.35 Mn |
| Jun 30, 2024 | 987.37 Mn |
| Mar 31, 2024 | 988.44 Mn |
| Dec 31, 2023 | 1.04 Bn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 1.11 Bn |
| Mar 31, 2023 | 1.17 Bn |
| Dec 31, 2022 | 1.22 Bn |
| Sep 30, 2022 | 1.30 Bn |
| Jun 30, 2022 | 1.42 Bn |
| Mar 31, 2022 | 1.50 Bn |
| Dec 31, 2021 | 1.61 Bn |
| Sep 30, 2021 | 1.73 Bn |